Patients seeking to treat the appearance of glabellar lines (also commonly referred to as 11 or frown lines) should get familiar with a new option that will be available in doctor’s offices as early as this spring: Jeuveau. On Friday, the FDA approved the new neuromodulator, marketed by medical aesthetics company Evolus, following two US Phase III trials and a global study of over 2,100 patients. Jeuveau will join the portfolio of neurotoxins available to US patients that currently include Botox Cosmetic, Dysport and Xeomin.
“Evolus is the first company in nearly a decade to enter the fast-growing U.S. aesthetic neurotoxin market,” says David Moatazedi, President and Chief Executive Officer of the company. It is also the first FDA-approved neurotoxin that is solely dedicated to aesthetics
You May Also Like: Will 2019 Be the Year of the Eco-Friendly Filler?
For consumers, Jeuveau will be priced on par with Botox Cosmetic and expected efficacy and length of duration is similar at three months. The drug was developed by South Korean pharmaceutical company Daewoong and first introduced to the Korean market in 2014 under the name Nabota.
Stay tuned to NewBeauty.com for updates.
